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Epstein-Barr Virus (EBV) is known to cause malignancies
in immunocompromised individuals, including lympho-
mas and lymphoproliferative disorders. Reactivation of
EBV from latency is important in the pathogenesis of
such malignancies. Therapeutically, oncolysis of tumors
harboring lytic EBV holds promise. However, exposure of
latently infected cultured B cells to lytic cycle inducing
stimuli results in virus reactivation within only 20% to
50% of cells. Host cell determinants, that govern this sus-
ceptibility to lytic reactivati o nw i t h i nl a t e n t l yi n f e c t e dB
cells, are not well understood. Our research has pre-
viously identified that higher levels of signal transducer
and activator of transcription 3 (STAT3) within cells cor-
relate with resistance to EBV lytic reactivation. We now
investigate whether inhibiting function of STAT3 pro-
motes susceptibility of latently infected B cells to known
lytic cycle inducing stimuli or results in induction of EBV
lytic cycle. We found that pharmacological inhibition of
STAT3 phosphorylation by Janus Kinase 2 (JAK2) inhibi-
tors (AG490 or WP1066) in latently infected cells
(HH514-16 Burkitt lymphoma and B95-8 lymphoblastoid
cells) increased lytic reactivation by chemical stimuli that
function by distinct mechanisms. Moreover, functional
inhibition of STAT3 alone resulted in lytic reactivation in
these cells. EBV-Lymphoblastoid cell lines (LCL) newly
generated from healthy individuals also demonstrated
increased susceptibility to lytic cycle inducing stimuli in
the presence of AG490 but variable susceptibility to lytic
reactivation when exposed to AG490 alone. Since this
lack of uniform response to AG490 alone could be due to
inadequate functional suppression of STAT3, we exam-
ined EBV-LCLs derived from patients with Autosomal
Dominant Hyperimmunoglobulin-E syndrome (AD-HIES
or Job syndrome). Patients with AD-HIES carry a domi-
nant negative mutation in their Stat3 gene resulting in
lower basal levels of functional STAT3. When LCLs from
AD-HIES patients were exposed to a JAK2 inhibitor
alone, we observed a strong increase in lytic reactivation
by expression of early and late lytic antigens over LCLs
derived from healthy individuals. Lytic reactivation in the
presence of AG490 occurred in these cells despite lack of
discernable increase from basal levels of expression of
ZEBRA, the viral lytic switch protein, when compared to
cells not exposed to AG490. Thus, STAT3 is important
in determining susceptibility to EBV reactivation. Fully
understanding how STAT3 governs such susceptibility
can lead to novel therapeutic strategies for EBV-related
diseases.
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